Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multi-year strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. Pfizer will leverage Tempus’ library…
Continue Reading
By Shania Kennedy
February 28, 2023 – New Jersey-based AtlantiCare is deploying pre-operative artificial intelligence (AI) assessment tools and robotic bronchoscopy techniques to support early lung cancer diagnosis and treatment.
The health system will leverage…
Dr. Ty Vachon, CEO & Co-Founder at Oatmeal HealthToday, cancer is the second leading cause of death in the United States. Sadly, cancer disparities exist, with racial/ethnic minority, low-income, and uninsured populations suffering the greatest burden. That’s why routine cancer screening is critical to addressing cancer disparities as they have the potential to greatly reduce both incidence and mortality rates. To address this, Federally qualified health centers (FQHCs) are funded by the Health Resources and Services Administration to provide preventive and primary healthcare services, including cancer screening, to the nation’s most vulnerable populations We recently sat down with Oatmeal Health’s Co-Founder and…
Continue Reading
G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity of the problems that can limit the use of this cancer treatment. Since trilaciclib’s initial approval insmall cell lung cancer, G1 has pursued more clinical trials that could support expanding the drug to other cancers. Colorectal cancer will no longer be one of them.
On Monday, G1 reported preliminary data showing that the placebo group outperformed the trilaciclib arm in helping patients live longer. G1 said it has decided to stop the colorectal cancer…
Subscribe for your weekly fix of health tech stories, wherever you get your news: Apple, Spotify or Twitter.Dr. Anne-Maree Cantwell, Partner at Empactful CapitalIn this episode, I sat down with Anne-Maree Cantwell, Venture Partner at…
Continue Reading
